Regeneron said U.S. net product sales of EYLEA decreased for the 3 months ended March 31, 2024 compared with the same period a year earlier. The company cited changing market dynamics, which resulted in lower volumes and a lower net selling price, as the main factors.

1. 01

   Regeneron said U.S. net product sales of EYLEA decreased for the 3 months ended March 31, 2024 compared with the same period a year earlier. The company cited changing market dynamics, which resulted in lower volumes and a lower net selling price, as the main factors.

2. 02

   The company said the increase in its share of profits from antibody commercialization for the 3 months ended March 31, 2024 was driven by higher profits from Dupixent sales. As of March 31, 2024, the contingent reimbursement obligation to Sanofi, or development balance, was approximately $2.200 billion.

3. 03

   The company attributed the increase in selling, general, and administrative expenses in Q1 2024 to higher costs related to supporting the launch of EYLEA HD and higher personnel-related costs. It said cost of goods sold rose due to higher preparation costs for the Rensselaer fill/finish facility, while cost of collaboration and contract manufacturing fell due to lower manufacturing costs for Dupixent.

4. 04

   The company said it expects capital expenditures for 2024 to be between $780 million and $880 million. As of March 31, 2024, the remaining limit under its existing share repurchase program was $1.233 billion, and in April 2024 its board approved a new program for an additional $3.0 billion.

Key figures

Quarter ended March 31, 2024

Revenue

$3.1B

Operating income

$751M

Net income

$722M

EPS

$6.27

Operating cash flow

$1.5B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.